Join
Live feed
·
PRReleasevia Quantisnow
Ionis Pharmaceuticals Inc. logo

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease

ByQuantisnow·Wall Street's wire, on your screen.
IONS· Ionis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IONS (Ionis Pharmaceuticals Inc.) and more on Quantisnow.

Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease | Quantisnow